Table of Content

Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Market Dynamics
Emerging Technologies
Analysis by Segment
Regional Analysis
Conclusion

Chapter 2 Market Overview
Overview and Market Definition
Different Microbiomes in Humans
Microbiome, Human Health and Disease
Technologies Aiding Microbiome Research
Culturing and Cultivation
Strategies for the Development of Microbiome Therapeutics
Additive Microbiome Therapy
Modulatory Microbiome Therapy
Analysis of Macroeconomic Factors
Geopolitical Factors
Inflation and Currency Exchange Fluctuations
Porter’s Five Forces Analysis

Chapter 3 Market Dynamics
Takeaways
Market Drivers
Growing Evidence of Microbiome-disease Correlation
Microbiome-based Diagnostics for Disease Prevention and Monitoring
Market Restraints
Challenges in Clinical Trial Design
Lack of Established Regulatory Frameworks
High Costs of Microbiome Therapeutics
Market Opportunities
Direct-to-Consumer Microbiome Testing
Drugs and Diagnostics for Lung and Skin Microbiomes

Chapter 4 Regulatory Landscape
Regulatory Aspects
North America
Europe
Asia-Pacific

Chapter 5 Emerging Technologies
Takeaways
Emerging Technologies
Microbial Ecosystem Therapeutics
Metatranscriptome Sequencing
Genetically Modified Microbiome Therapeutics
Combination and Adjuvant Therapies with Microbiome-based Drugs
Novel Preclinical Models

Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Market Analysis by Type
Microbiome-based Drugs
Market Analysis by Application
Infectious Diseases
GI Disorders
Metabolic Disorders
Cancer
Other Diseases
Market Analysis by End User
Hospitals and Clinics
Research Institutions
Pharmaceutical Companies
Geographic Breakdown
Market Analysis by Region
North America
Europe
Asia-Pacific
South America
Middle East and Africa

Chapter 7 Competitive Intelligence
Takeaways
Company Share Analysis
Competitive Analysis
Venture Funding and Investment Landscape
Recent Developments

Chapter 8 Sustainability in the Human Microbiome-based Drugs and Diagnostics Industry: An ESG Perspective
Introduction to ESG
ESG Risk Ratings
Concluding Remarks

Chapter 9 Appendix
Methodology
Sources
Abbreviations
Company Profiles
BIOMEBANK
ENTEROBIOTIX LTD.
ENTEROME
FERRING
GENETIC ANALYSIS
ILLUMINA INC.
MICROBIOME INSIGHTS
MICROBIOTICA
NESTLE HEALTH SCIENCE
OXFORD NANOPORE TECHNOLOGIES PLC
PACBIO
SFA THERAPEUTICS INC.
THERMO FISHER SCIENTIFIC INC.
VEDANTA BIOSCIENCES INC.
Emerging Start-ups/Market Disruptors



List of Figures


Summary Figure : Global Market Shares of Human Microbiome-based Drugs and Diagnostics, by Region, 2024
Figure 1 : Essential Functions of the Human Microbiome
Figure 2 : Porter’s Five Forces Analysis of the Human Microbiome-based Drugs and Diagnostics Market
Figure 3 : Human Microbiome-based Drugs and Diagnostics Market Dynamics
Figure 4 : Diseases and Conditions Associated with Dysbiosis
Figure 5 : Global Market Shares of Human Microbiome-based Drugs and Diagnostics, by Type, 2024
Figure 6 : Global Market Shares of Human Microbiome-based Drugs and Diagnostics, by Application, 2024
Figure 7 : Global Market Shares of Human Microbiome-based Drugs and Diagnostics, by End User, 2024
Figure 8 : Global Market Shares of Human Microbiome-based Drugs and Diagnostics, by Region, 2024
Figure 9 : North American Market Shares of Human Microbiome-based Drugs and Diagnostics, by Country, 2024
Figure 10 : European Market Shares of Human Microbiome-based Drugs and Diagnostics, by Country, 2024
Figure 11 : Asia-Pacific Market Shares of Human Microbiome-based Drugs and Diagnostics, by Country, 2024
Figure 12 : Company Shares in the Human Microbiome-based Drug Market, 2024
Figure 13 : Ferring: Revenue Share, by Business Unit, FY 2023
Figure 14 : Ferring: Revenue Share, by Country/Region, FY 2023
Figure 15 : Genetic Analysis: Revenue Share, by Business Unit, FY 2024
Figure 16 : Genetic Analysis: Revenue Share, by Country/Region, FY 2024
Figure 17 : Illumina Inc.: Revenue Share, by Business Unit, FY 2024
Figure 18 : Illumina Inc.: Revenue Share, by Country/Region, FY 2024
Figure 19 : Oxford Nanopore Technologies plc: Revenue Share, by Business Unit, FY 2024
Figure 20 : Oxford Nanopore Technologies plc: Revenue Share, by Country/Region, FY 2024
Figure 21 : PacBio: Revenue Share, by Business Unit, FY 2024
Figure 22 : PacBio: Revenue Share, by Country/Region, FY 2024
Figure 23 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2024
Figure 24 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2024

List of Tables


Summary Table : Global Market for Human Microbiome-based Drugs and Diagnostics, by Region, Through 2030
Table 1 : Technology for Microbiome Research
Table 2 : Diseases Associated with Microbiome Dysbiosis
Table 3 : Microbiome-based Drug Nomenclature
Table 4 : Global Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030
Table 5 : Global Market for Human Microbiome-based Drugs, by Route of Administration, Through 2030
Table 6 : Global Market for Human Microbiome-based Drugs, by Region, Through 2030
Table 7 : Global Market for Human Microbiome-based Drugs, by Rectal Route of Administration, by Region, Through 2030
Table 8 : Global Market for Human Microbiome-based Drugs, by Oral Route of Administration, by Region, Through 2030
Table 9 : Global Market for Human Microbiome-based Diagnostics, by Region, Through 2030
Table 10 : Global Market for Human Microbiome-based Diagnostics, by Product Type, Through 2030
Table 11 : Global Market for Human Microbiome-based Diagnostics Reagents and Kits, by Region, Through 2030
Table 12 : Global Market for Human Microbiome-based Diagnostic Instruments, by Region, Through 2030
Table 13 : Global Market for Human Microbiome-based Drugs and Diagnostics, by Application, Through 2030
Table 14 : Global Market for Human Microbiome-based Drugs and Diagnostics for Infectious Diseases, by Region, Through 2030
Table 15 : Global Market for Human Microbiome-based Drugs and Diagnostics for GI Disorders, by Region, Through 2030
Table 16 : Global Market for Human Microbiome-based Drugs and Diagnostics for Metabolic Disorders, by Region, Through 2030
Table 17 : Global Market for Human Microbiome-based Drugs and Diagnostics for Cancer, by Region, Through 2030
Table 18 : Microbiome-based Drugs in the Pipeline for Cancer Therapy
Table 19 : Global Market for Human Microbiome-based Drugs and Diagnostics for Other Diseases, by Region, Through 2030
Table 20 : Global Market for Human Microbiome-based Drugs and Diagnostics, by End User, Through 2030
Table 21 : Global Market for Microbiome-based Drugs and Diagnostics for Hospitals and Clinics, by Region, Through 2030
Table 22 : Global Market for Microbiome-based Drugs and Diagnostics for Research Institutions, by Region, Through 2030
Table 23 : Global Market for Microbiome-based Drugs and Diagnostics for Pharmaceutical Firms, by Region, Through 2030
Table 24 : Global Market for Human Microbiome-based Drugs and Diagnostics, by Region, Through 2030
Table 25 : North American Market for Human Microbiome-based Drugs and Diagnostics, by Country, Through 2030
Table 26 : North American Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030
Table 27 : North American Market for Microbiome-based Drugs, by Route of Administration, Through 2030
Table 28 : North American Market for Microbiome-based Diagnostics, by Product Type, Through 2030
Table 29 : North American Market for Microbiome-based Drugs and Diagnostics, by Application, Through 2030
Table 30 : North American Market for Microbiome-based Drugs and Diagnostics, by End User, Through 2030
Table 31 : European Market for Human Microbiome-based Drugs and Diagnostics, by Country, Through 2030
Table 32 : European Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030
Table 33 : European Market for Microbiome-based Drugs, by Route of Administration, Through 2030
Table 34 : European Market for Microbiome-based Diagnostics, by Product Type, Through 2030
Table 35 : European Market for Microbiome-based Drugs and Diagnostics, by Application, Through 2030
Table 36 : European Market for Microbiome-based Drugs and Diagnostics, by End User, Through 2030
Table 37 : Asia-Pacific Market for Human Microbiome-based Drugs and Diagnostics, by Country, Through 2030
Table 38 : Asia-Pacific Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030
Table 39 : Asia-Pacific Market for Microbiome-based Drugs, by Route of Administration, Through 2030
Table 40 : Asia-Pacific Market for Microbiome-based Diagnostics, by Product Type, Through 2030
Table 41 : Asia-Pacific Market for Microbiome-based Drugs and Diagnostics, by Application, Through 2030
Table 42 : Asia-Pacific Market for Microbiome-based Drugs and Diagnostics, by End User, Through 2030
Table 43 : South American Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030
Table 44 : South American Market for Microbiome-based Drugs, by Route of Administration, Through 2030
Table 45 : South American Market for Microbiome-based Diagnostics, by Product Type, Through 2030
Table 46 : South American Market for Microbiome-based Drugs and Diagnostics, by Application, Through 2030
Table 47 : South American Market for Microbiome-based Drugs and Diagnostics, by End User, Through 2030
Table 48 : MEA Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030
Table 49 : MEA Market for Microbiome-based Drugs, by Administration Route, Through 2030
Table 50 : MEA Market for Microbiome-based Diagnostics, by Product Type, Through 2030
Table 51 : MEA Market for Microbiome-based Drugs and Diagnostics, by Application, Through 2030
Table 52 : MEA Market for Microbiome-based Drugs and Diagnostics, by End User, Through 2030
Table 53 : Competitive Analysis of Human Microbiome-based Diagnostics Market
Table 54 : Venture Funding in the Human Microbiome-based Drugs and Diagnostics Market, 2024
Table 55 : Recent Developments in the Human Microbiome-based Drug and Diagnostics Market, 2022–2025
Table 56 : ESG Goals of Human Microbiome-based Drugs and Diagnostics Companies
Table 57 : ESG Risk Ratings for Human Microbiome-based Drugs and Diagnostics Firms, 2025
Table 58 : Report Information Sources
Table 59 : Abbreviations Used in this Report
Table 60 : BiomeBank: Company Snapshot
Table 61 : BiomeBank: Product Portfolio
Table 62 : BiomeBank: News/Key Developments, 2024
Table 63 : EnteroBiotix Ltd.: Company Snapshot
Table 64 : EnteroBiotix Ltd.: Product Portfolio
Table 65 : EnteroBiotix Ltd.: News/Key Developments, 2024
Table 66 : Enterome: Company Snapshot
Table 67 : Enterome: Product Portfolio
Table 68 : Enterome: News/Key Developments, 2022
Table 69 : Ferring: Company Snapshot
Table 70 : Ferring: Financial Performance, FY 2022 and 2023
Table 71 : Ferring: Product Portfolio
Table 72 : Ferring: News/Key Developments, 2022 and 2023
Table 73 : Genetic Analysis: Company Snapshot
Table 74 : Genetic Analysis: Financial Performance, FY 2023 and 2024
Table 75 : Genetic Analysis: Product Portfolio
Table 76 : Genetic Analysis: News/Key Developments, 2024
Table 77 : Illumina Inc.: Company Snapshot
Table 78 : Illumina Inc.: Financial Performance, FY 2023 and 2024
Table 79 : Illumina Inc.: Product Portfolio
Table 80 : Microbiome Insights: Company Snapshot
Table 81 : Microbiome Insights: Product Portfolio
Table 82 : Microbiome Insights: News/Key Developments, 2024
Table 83 : Microbiotica: Company Snapshot
Table 84 : Microbiotica: Product Portfolio
Table 85 : Microbiotica: News/Key Developments, 2023
Table 86 : Nestle Health Science: Company Snapshot
Table 87 : Nestle Health Science: Product Portfolio
Table 88 : Nestle Health Science: News/Key Developments, 2024
Table 89 : Oxford Nanopore Technologies plc: Company Snapshot
Table 90 : Oxford Nanopore Technologies plc: Financial Performance, FY 2023 and 2024
Table 91 : Oxford Nanopore Technologies plc.: Product Portfolio
Table 92 : PacBio: Company Snapshot
Table 93 : PacBio: Financial Performance, FY 2023 and 2024
Table 94 : PacBio: Product Portfolio
Table 95 : PacBio: News/Key Developments, 2025
Table 96 : SFA Therapeutics Inc.: Company Snapshot
Table 97 : SFA Therapeutics Inc.: Product Portfolio
Table 98 : SFA Therapeutics Inc.: News/Key Developments, 2024
Table 99 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 100 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024
Table 101 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 102 : Vedanta Biosciences Inc.: Company Snapshot
Table 103 : Vedanta Biosciences Inc.: Product Portfolio
Table 104 : Vedanta Biosciences Inc.: News/Key Developments, 2023
Table 105 : Emerging Startups